July 15, 2016

Nancy Rizzo, Ph.D.
EPIC Research & Diagnostics, Inc.
7659 E. Pinnacle Peak Road
Suite 115
Scottsdale, AZ 85255

Re: DEN150004
EPIC ClearView™ System
Evaluation of Automatic Class III Designation – De Novo Request
Regulation Number: 21 CFR 882.1561
Regulation Name: Evoked Photon Image Capture Device
Regulatory Classification: Class I
Product Code: PNA
Dated: January 12, 2015
Received: January 13, 2015

Dear Dr. Rizzo:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your de novo request for classification of the EPIC ClearView™ System, a prescription device under 21 CFR Part 801.109 that is indicated for the following:

The ClearView™ System provides two sets of numbers under two different conditions, one with capacitive barrier to minimize the effect of variables such as oils and perspiration on the image and one without the capacitive barrier. The device provides numerical measures of electrophysiological signals emanating from the skin. The device is limited to use as a measurement tool and is not intended for diagnostic purposes or for influencing any clinical decisions. This device is only to be used to image and document electrophysiological signals emanating from the skin. Clinical management decisions should be made on the basis of routine clinical care and professional judgment in accordance with standard medical practice.

FDA concludes that this device should be classified into class I. This order, therefore, classifies the EPIC ClearView™ System, and substantially equivalent devices of this generic type, into class I under the generic name, Evoked Photon Image Capture Device.

FDA identifies this generic type of device as:

**Evoked Photon Image Capture Device.** An evoked photon image capture device is a prescription, electrically powered device intended for use as a non-invasive
measurement tool that applies electricity to detect electrophysiological signals emanating from the skin, which are reported numerically and as images without clinical interpretation. The device is not intended for diagnostic purposes.

Section 513(f)(2) of the Food, Drug and Cosmetic Act (the FD&C Act) was amended by section 607 of the Food and Drug Administration Safety and Innovation Act (FDASIA) on July 9, 2012. This new law provides two options for de novo classification. First, any person who receives a "not substantially equivalent" (NSE) determination in response to a 510(k) for a device that has not been previously classified under the Act may, within 30 days of receiving notice of the NSE determination, request FDA to make a risk-based classification of the device under section 513(a)(1) of the Act. Alternatively, any person who determines that there is no legally marketed device upon which to base a determination of substantial equivalence may request FDA to make a risk-based classification of the device under section 513(a)(1) of the Act without first submitting a 510(k). FDA shall, within 120 days of receiving such a request, classify the device. This classification shall be the initial classification of the device. Within 30 days after the issuance of an order classifying the device, FDA must publish a notice in the Federal Register classifying the device type.

On January 13, 2015, FDA received your de novo requesting classification of the EPIC ClearView™ System into class I. The request was submitted under section 513(f)(2) of the FD&C Act. In order to classify the EPIC ClearView™ System into class I or II, it is necessary that the proposed class have sufficient regulatory controls to provide reasonable assurance of the safety and effectiveness of the device for its intended use.

After review of the information submitted in the de novo request, FDA has determined that the EPIC ClearView™ System indicated for the following indications for use can be classified in class I.

The ClearView™ System provides two sets of numbers under two different conditions, one with capacitive barrier to minimize the effect of variables such as oils and perspiration on the image and one without the capacitive barrier. The device provides numerical measures of electrophysiological signals emanating from the skin. The device is limited to use as a measurement tool and is not intended for diagnostic purposes or for influencing any clinical decisions. This device is only to be used to image and document electrophysiological signals emanating from the skin. Clinical management decisions should be made on the basis of routine clinical care and professional judgment in accordance with standard medical practice.

FDA believes that class I (general) controls provide reasonable assurance of the safety and effectiveness of the device type. The identified risks to health are adverse tissue reaction, electromagnetic incompatibility, and electromagnetic malfunction (e.g., shock).

The Evoked Photon Image Capture Device is subject to the general controls of the FD&C Act. Section 510(l) of the FD&C Act (21 U.S.C. 360(l)) provides that a class I device is not subject to the premarket notification requirements under section 510(k) of the FD&C Act unless the device is of substantial importance in preventing impairment of human health or presents a potential unreasonable risk of illness or injury. FDA has determined that the device does meet these criteria and, therefore, premarket notification is not required for the device. Thus, persons who intend to
market this device need not submit a premarket notification containing information on the Evoked Photon Image Capture Device they intend to market prior to marketing the device subject to the limitations on exemptions in 21 CFR 882.9.

In addition, this is a prescription device and must comply with 21 CFR 801.109.

Please be advised that FDA’s decision to grant this *de novo* request does not mean that FDA has made a determination that your device complies with other requirements of the FD&C Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the FD & C Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the FD & C Act); 21 CFR 1000-1050.

A notice announcing this classification order will be published in the *Federal Register*. A copy of this order and supporting documentation are on file in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852 and are available for inspection between 9 a.m. and 4 p.m., Monday through Friday.

As a result of this order, you may immediately market your device as described in the *de novo* request, subject to the general control provisions of the FD&C Act.

If you have any questions concerning this classification order, please contact Kristen A. Bowsher, Ph.D. at Kristen.Bowsher@fda.hhs.gov or (301) 796-6448.

Sincerely,

Randall G. Brockman -S

for Jonette Foy, Ph.D.
Deputy Director
for Engineering and Science Review
Office of Device Evaluation
Center for Devices and
Radiological Health